A Phase 1 interventional study of PC14586 in Healthy Volunteers, sponsored by PMV Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-13.
Sponsored by PMV Pharmaceuticals, Inc · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a 2-part Phase 1 cross-over study to assess the effects of food on the pharmacokinetics of PC14586 in healthy volunteers. The pharmacokinetics of PC14586 at a clinically relevant dose in Japanese participants will also be studied.
PC14586 is a first-in-class, oral, small molecule p53 reactivator that is selective for the p53 Y220C mutation. This Phase 1 trial will be conducted in 2 parts (Part 1 - pilot and Part 2 - pivotal) to assess the pharmacokinetics of PC14586 in healthy volunteers including Japanese participants.
PMV Pharmaceuticals, Inc is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Inclusion criteria for Japanese participants only:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1 will be fed, then washout, then Period 2 will be fasted.
Drug: PC14586
Period 1 will be fasted, then washout, then Period 2 will be fed.
Drug: PC14586
Period 1 will be fed, then washout, then Period 2 will be fasted. A different dose of PC14586 will be tested.
Drug: PC14586
Period 1 will be fasted, then washout, then Period 2 will be fed. A different dose of PC14586 will be tested.
Drug: PC14586
6 Japanese participants will be administered a single dose of PC14586.
Drug: PC14586
An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).
Part 1: Effect of a high-fat meal on AUClast
Time frame: 2 months
Part 1: Effect of a high-fat meal on AUC0-inf
Time frame: 2 months
Part 1: Effect of a high-fat meal on the Tmax
Time frame: 2 months
Part 1: Effect of a high-fat meal on the Cmax
Time frame: 2 months
Part 2: Effect of a high-fat meal on the AUC0-last
Time frame: 7 months
Part 2: Effect of a high-fat meal on the AUC0-inf
Time frame: 7 months
Part 2: Effect of a high-fat meal on the Tmax
Time frame: 7 months
Part 2: Effect of a high-fat meal on the Cmax
Time frame: 7 months
Part 1: Treatment emergent adverse events (TEAE)
Time frame: 5 months
Part 1: Clinically relevant changes in: physical examinations, vital signs, clinical laboratory tests, 12-lead triplicate electrocardiogram (ECG)
Time frame: 5 months
Part 2: AUC0-last of PC14586
Time frame: 6 months
Part 2: AUC0-inf of PC14586
Time frame: 6 months
Part 2: Cmax of PC14586
Time frame: 6 months
Part 2: Tmax of PC14586
Time frame: 6 months
Part 2: The apparent clearance (CL/F) of PC14586
Time frame: 6 months
Part 2: Volume of distribution (Vz/F) of PC14586
Time frame: 6 months
Half-life of PC14586
Time frame: 6 months
Part 2: Incidence of Treatment emergent adverse events (TEAE)
Time frame: 10 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2021 to primary completion in Jun 2022, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rezatapopt
PMV Pharmaceuticals, Inc